Provided herein, in some embodiments, are methods of treating a cancer characterized by the presence of a mutant p53 protein in a subject in need thereof, comprising administering to the subject an effective amount of a STAT3 inhibitor.
Provided herein, in some embodiments, are solid-state forms of a compound represented by Formula (I), as free acid or base, or a pharmaceutically acceptable salt or solvate thereof, pharmaceutical compositions comprising one or more solid-state forms of a compound represented by Formula (I), as free acid or base, or a pharmaceutically acceptable salt or solvate thereof, and methods of use thereof.
C07C 311/00 - Amides d'acides sulfoniques, c.-à-d. composés comportant des atomes d'oxygène, liés par des liaisons simples, de groupes sulfoniques remplacés par des atomes d'azote, ne faisant pas partie de groupes nitro ou nitroso
Provided herein are solid amorphous dispersions, compositions, and solid oral dosage forms comprising a compound of Formula (I). In specific instances, such compositions comprise a polymer excipient, and optionally a crystallization inhibiting polymer. In some instances, such compositions are useful for the treatment of fibrosis, cancer, and/or inflammatory disease/disorder.
Provided herein are methods of treating a cancer in a subject in need thereof, comprising administering to the subject an effective amount of a STAT inhibitor and an effective amount of an immune checkpoint inhibitor (e.g., PD-1 inhibitor or PD-L1 inhibitor).
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
5.
FORMULATIONS OF STAT3 INHIBITORS AND METHODS OF USE THEREOF
Provided herein are methods of treating cancer in a subject in need thereof, comprising administering to the subject certain doses of a composition comprising a compound of Formula (I) and a polymer excipient.
Provided herein, in certain embodiments, are compounds of Formula I:
or a pharmaceutically acceptable salt or a solvate thereof, compositions comprising a compounds of Formula I, or a pharmaceutically acceptable salt or a solvate thereof, and uses thereof such as in treating certain diseases or disorders (e.g., cancer, fibrosis, chronic inflammation).
Provided herein, in certain embodiments, are compounds of Formula I:
or a pharmaceutically acceptable salt or a solvate thereof, compositions comprising a compounds of Formula I, or a pharmaceutically acceptable salt or a solvate thereof, and uses thereof such as in treating certain diseases or disorders (e.g., cancer, fibrosis, chronic inflammation).
Provided herein, in some embodiments, are methods of treating a subject diagnosed with a non-viral liver cancer, the method comprising administering to the subject an effective amount of a STAT3 inhibitor.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
Compounds as STAT3 inhibitors are described. A pharmaceutical composition comprising the same, methods of making the same, and a method for treating or preventing conditions such as cancer, chronic inflammation, and fibrosis using the same, are described.
C07C 311/29 - Sulfonamides, le squelette carboné de la partie acide étant substitué de plus par des atomes d'oxygène liés par des liaisons simples ayant l'atome de soufre d'au moins un des groupes sulfonamide lié à un atome de carbone d'un cycle aromatique à six chaînons
9.
THERAPEUTIC COMPOUNDS, FORMULATIONS, AND USE THEREOF
The present disclosure, in part, is directed to compositions comprising a compound of formula (I):
The present disclosure, in part, is directed to compositions comprising a compound of formula (I):
The present disclosure, in part, is directed to compositions comprising a compound of formula (I):
wherein the compositions are substantially free of an impurity, processes of producing thereof, and uses thereof.
The present disclosure, in part, is directed to compositions comprising a compound of formula (I): wherein the compositions are substantially free of an impurity, processes of producing thereof, and uses thereof.
C07C 303/38 - Préparation d'esters ou d'amides d'acides sulfuriquesPréparation d'acides sulfoniques ou de leurs esters, halogénures, anhydrides ou amides d'amides d'acides sulfoniques par réaction d'ammoniac ou d'amines avec des acides sulfoniques ou avec leurs esters, leurs anhydrides ou leurs halogénures
C07C 303/40 - Préparation d'esters ou d'amides d'acides sulfuriquesPréparation d'acides sulfoniques ou de leurs esters, halogénures, anhydrides ou amides d'amides d'acides sulfoniques par des réactions n'impliquant pas la formation de groupes sulfonamide
C07C 311/29 - Sulfonamides, le squelette carboné de la partie acide étant substitué de plus par des atomes d'oxygène liés par des liaisons simples ayant l'atome de soufre d'au moins un des groupes sulfonamide lié à un atome de carbone d'un cycle aromatique à six chaînons
Provided herein, in certain embodiments, are compounds of Formula I.
or a pharmaceutically acceptable salt or a solvate thereof, compositions comprising a compounds of Formula I, or a pharmaceutically acceptable salt or a solvate thereof, and uses thereof such as in treating certain diseases or disorders (e.g., cancer, fibrosis, chronic inflammation).
((Formula I:) or a pharmaceutically acceptable salt or a solvate thereof, compositions comprising a compounds of Formula I, or a pharmaceutically acceptable salt or a solvate thereof, and uses thereof such as in treating certain diseases or disorders (e.g., cancer, fibrosis, chronic inflammation).
Provided herein are compositions, formulations, and (e.g., oral) dosage forms comprising a compound of Formula (I). In specific instances, such compositions comprise an emulsifier, a solubilizer, a polyethylene glycol, a surfactant, and an antioxidant. In some instances, such compositions are useful for the treatment of fibrosis, cancer, and/or chronic inflammation.
Provided herein are solid amorphous dispersions, compositions, and solid oral dosage forms comprising a compound of Formula (I). In specific instances, such compositions comprise a polymer excipient, and optionally a crystallization inhibiting polymer. In some instances, such compositions are useful for the treatment of fibrosis, cancer, and/or inflammatory disease/disorder.
Provided herein are methods of treating a cancer in a subject in need thereof, comprising administering to the subject an effective amount of a STAT inhibitor and an effective amount of an immune checkpoint inhibitor (e.g., PD-1 inhibitor or PD-L1 inhibitor).
Embodiments of the disclosure encompass methods of treating insulin resistance in an individual in need thereof by administering one or more STAT3 inhibitors to the individual. In specific aspects, the methods allow for reversing insulin resistance in individuals. The STAT3 inhibitor may be one or more particular small molecules encompassed herein.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
(1) Pharmaceutical preparations for treating cancer, inflammation and fibrosis; pharmaceutical and therapeutic preparations (1) Research and development of pharmaceutical services
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Pharmaceutical preparations for treating cancer, inflammation and fibrosis; pharmaceutical and therapeutic preparations. Research and development of pharmaceutical services.
Provided herein are compositions, formulations, and (e.g., oral) dosage forms comprising a compound of Formula (I). In specific instances, such compositions comprise an emulsifier, a solubilizer, a polyethylene glycol, a surfactant, and an antioxidant. In some instances, such compositions are useful for the treatment of fibrosis, cancer, and/or chronic inflammation.
Provided herein are compositions, formulations, and (e.g., oral) dosage forms comprising a compound of Formula (I). In specific instances, such compositions comprise an emulsifier, a solubilizer, a polyethylene glycol, a surfactant, and an antioxidant. In some instances, such compositions are useful for the treatment of fibrosis, cancer, and/or chronic inflammation.
Provided herein are compositions, formulations, and (e.g., oral) dosage forms comprising a compound of Formula (I). In specific instances, such compositions comprise an emulsifier, a solubilizer, a polyethylene glycol, a surfactant, and an antioxidant. In some instances, such compositions are useful for the treatment of fibrosis, cancer, and/or chronic inflammation.
Embodiments of the disclosure encompass methods of treating insulin resistance in an individual in need thereof by administering one or more STAT3 inhibitors to the individual. In specific aspects, the methods allow for reversing insulin resistance in individuals. The STAT3 inhibitor may be one or more particular small molecules encompassed herein.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
Compounds as STAT3 inhibitors are described. A pharmaceutical composition comprising the same, methods of making the same, and a method for treating or preventing conditions such as cancer, chronic inflammation, and fibrosis using the same, are described.
Compounds as STAT3 inhibitors are described. A pharmaceutical composition comprising the same, methods of making the same, and a method for treating or preventing conditions such as cancer, chronic inflammation, and fibrosis using the same, are described.
C07C 311/29 - Sulfonamides, le squelette carboné de la partie acide étant substitué de plus par des atomes d'oxygène liés par des liaisons simples ayant l'atome de soufre d'au moins un des groupes sulfonamide lié à un atome de carbone d'un cycle aromatique à six chaînons
28.
THERAPEUTIC COMPOUNDS, FORMULATIONS, AND USES THEREOF
Provided herein are compositions, formulations, and (e.g., oral) dosage forms comprising a compound of Formula (I). In specific instances, such compositions comprise an emulsifier, a solubilizer, a polyethylene glycol, a surfactant, and an antioxidant. In some instances, such compositions are useful for the treatment of fibrosis, cancer, and/or chronic inflammation.
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C07C 311/29 - Sulfonamides, le squelette carboné de la partie acide étant substitué de plus par des atomes d'oxygène liés par des liaisons simples ayant l'atome de soufre d'au moins un des groupes sulfonamide lié à un atome de carbone d'un cycle aromatique à six chaînons
29.
THERAPEUTIC COMPOUNDS, FORMULATIONS, AND USE THEREOF
Provided herein are solid amorphous dispersions, compositions, and solid oral dosage forms comprising a compound of Formula (I). In specific instances, such compositions comprise a polymer excipient, and optionally a crystallization inhibiting polymer. In some instances, such compositions are useful for the treatment of fibrosis, cancer, and/or inflammatory disease/disorder.
Provided herein are methods of treating a cancer in a subject in need thereof, comprising administering to the subject an effective amount of a STAT inhibitor and an effective amount of an immune checkpoint inhibitor (e.g., PD-1 inhibitor or PD-L1 inhibitor).
A61K 31/27 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carbamiques ou thiocarbamiques, p. ex. méprobamate, carbachol, néostigmine
A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil
A61K 31/64 - Sulfonylurées, p. ex. glibenclamide, tolbutamide, chlorpropamide
A61K 31/661 - Acides du phosphore ou leurs esters n'ayant pas de liaison P-C, p. ex. fosfosal, dichlorvos, malathion
A61P 19/04 - Médicaments pour le traitement des troubles du squelette des troubles non-spécifiques du tissu conjonctif
A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques
C07C 311/29 - Sulfonamides, le squelette carboné de la partie acide étant substitué de plus par des atomes d'oxygène liés par des liaisons simples ayant l'atome de soufre d'au moins un des groupes sulfonamide lié à un atome de carbone d'un cycle aromatique à six chaînons
C07D 207/09 - Radicaux substitués par des atomes d'azote ne faisant pas partie d'un radical nitro
C07F 9/12 - Esters des acides phosphoriques avec des composés hydroxyarylés
32.
THERAPEUTIC COMPOUNDS FOR METHODS OF USE IN INSULIN RESISTANCE
Embodiments of the disclosure encompass methods of treating insulin resistance in an individual in need thereof by administering one or more STAT3 inhibitors to the individual. In specific aspects, the methods allow for reversing insulin resistance in individuals. The STAT3 inhibitor may be one or more particular small molecules encompassed herein.
C07C 303/38 - Préparation d'esters ou d'amides d'acides sulfuriquesPréparation d'acides sulfoniques ou de leurs esters, halogénures, anhydrides ou amides d'amides d'acides sulfoniques par réaction d'ammoniac ou d'amines avec des acides sulfoniques ou avec leurs esters, leurs anhydrides ou leurs halogénures
C07C 303/40 - Préparation d'esters ou d'amides d'acides sulfuriquesPréparation d'acides sulfoniques ou de leurs esters, halogénures, anhydrides ou amides d'amides d'acides sulfoniques par des réactions n'impliquant pas la formation de groupes sulfonamide
C07C 311/29 - Sulfonamides, le squelette carboné de la partie acide étant substitué de plus par des atomes d'oxygène liés par des liaisons simples ayant l'atome de soufre d'au moins un des groupes sulfonamide lié à un atome de carbone d'un cycle aromatique à six chaînons
